List of Adhansia Xr drug patents

Adhansia Xr is owned by Purdue Pharma Lp.

Adhansia Xr contains Methylphenidate Hydrochloride.

Adhansia Xr has a total of 12 drug patents out of which 0 drug patents have expired.

Adhansia Xr was authorised for market use on 27 February, 2019.

Adhansia Xr is available in capsule, extended release;oral dosage forms.

Adhansia Xr can be used as method of treating attention deficit hyperactivity disorder (adhd).

The generics of Adhansia Xr are possible to be released after 19 November, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10292938 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10512612 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10292939 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10512613 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10449159 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10500162 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10568841 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10111839 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10507186 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10688060 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US9974752 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10722473 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Nov, 2038

(15 years from now)

Do you want to check out ADHANSIA XR patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Jun 28, 2024

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 February, 2019

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

ADHANSIA XR family patents

16

United States

7

Canada

3

Australia

2

Chile

2

Singapore

2

Japan

1

Korea, Republic of

1

China

1

Hong Kong

1

South Africa

1

Israel

1

Taiwan

1

Brazil

1

Argentina

EA

1

EA

1

Mexico

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in